At the 2025 American Academy of Neurology meeting, Fernandez et al. (2025) reported that adjunctive Tavapadon lengthened daily “good ON” time by ~1.1 h and cut “OFF” periods by nearly 1 h without increasing troublesome dyskinesia, aligning with the promise of continuous D1R/D5R activation [20]. This evidence concerns the gene DRD1 and drug-induced dyskinesia.